| 产品编号 | BIO0999SM |
| 英文名称 | Anti-HER2/neu Reference Antibody (Zanidatamab Biosimilar) |
| 别 名 | ERBB2 / HER2 / CD340; Zanidatamab |
| 抗体来源 | |
| 克隆类型 | Monoclonal |
| 交叉反应 | Human |
| 产品应用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理论分子量 | 124.81kDa |
| 性 状 | Lyophilized |
| 亚 型 | Half IgG+ScFv |
| 纯化方法 | Protein A |
| 缓 冲 液 | 100 mM Pro-Ac 20mM Arg pH 5.0 |
| 保存条件 | -80°C for 2 years under sterile conditions； -20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 产品介绍 | |
| 产品图片 |
Co-incubation of Zanidatamab with BT474 cell and PBMCs for 4 hours, then LDH was detected to evaluate the ADCC activity of Zanidatamab. As shown in fig, Zanidatamab has ADCC activity, and the IC50 was 0.023 nM.
Zanidatamab bound to BT474 cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Zanidatamab bound to BT474 cells, and the EC50 was 3.061 nM.
Zanidatamab bound to HER2 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Zanidatamab bound to hu-HER2-his, and the EC50 was 0.012 nM.
The purity of Anti-HER2/neu Reference Antibody (Zanidatamab) is 98.25%, determined by SEC-HPLC.
Anti-HER2/neu Reference Antibody (Zanidatamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The detected molecular weight of Anti-HER2/neu Reference Antibody (Zanidatamab) is 124.82 kDa.
|
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
